Video
Trial investigates negative predictive value of cystoscopic examinations in patients with bladder cancer
Author(s):
"The problem is that we are not very good at predicting who is not harboring any cancer in their bladder,” says Alexander Kutikov, MD, FACS.
Video Player is loading.
In this video, Alexander Kutikov, MD, FACS, discusses his presentation, “Can systematic bladder sampling predict pT0?” which was part of the bladder cancer course at the 2021 Society of Urologic Oncology Annual Meeting. Kutikov is the chief of the division of urology and urologic oncology, professor in the department of surgical oncology, and the Roberta R. Scheller Chair in urologic oncology at the Fox Chase Cancer Center at Temple University in Philadelphia, Pennsylvania.
Related Videos
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Related Content
